Maturation of intestinal innate immunity and NEC

肠道先天免疫和NEC的成熟

基本信息

  • 批准号:
    8220976
  • 负责人:
  • 金额:
    $ 46.31万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-02-12 至 2014-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): A family of Toll-Like Receptors (TLRs) stimulates the innate immune system upon encountering microbial pattern molecules, lipopolysaccharide [LPS] or peptidoglycans [PG]. When the gastrointestinal tract is initially colonized by microbes at birth, the mucosal innate immune system requires attenuation to avoid chronic inflammation by activation of TLR pathways. In term infants, perinatal downregulation of intestinal TLRs may provide this attenuation. In premature infants born before this developmental regulation, intestinal colonization could activate TLR pathways, leading to chronic inflammation. An inappropriate immune response to bacterial exposure could lead to generalized inflammation and bowel necrosis, such as occurs in necrotizing enterocolitis (NEC). In this proposal, we will study the ontogeny of TLR receptor expression, signaling, and inhibition, and determine its role in regulating innate immune responses. Steroids and probiotic therapy have been shown to prevent the onset of some premature infants predisposed to NEC. The mechanism of steroid action and the role of probiotic therapy will be determined. The probiotic factors that prevent excessive activation of the gut epithelium by microflora in term infants will be identified. The hypothesis is that colonization of the premature infant gut prior to maturation of the TLR signaling pathway can lead to excessive inflammation of the infant gut characteristic of NEC. The capacity of health-promoting probiotic bacteria to accelerate ontogeny of negative regulators of TLR pathways, thereby preventing excessive inflammation, will be investigated. We have developed specific human in-vivo and in-vitro intestinal models for gut inflammation to address this hypothesis. Our specific aims address whether: (1) coordinated downregulation of TLR receptors and its signaling intermediates and negative regulators prevents excessive inflammatory response to bacterial colonization at birth; (2) pretreatment with glucocorticoids prevents hyperresponsiveness to newly colonizing bacteria by inducing maturation of the TLR signaling pathways in premature gut; and (3) probiotic factors prevent the onset of NEC by accelerating the maturation of the TLR signaling pathways in premature gut. The successful completion of this project will provide novel basic information on the ontogeny of the control elements of TLR signaling pathways, and their modulation by steroids and probiotics. This mechanistic understanding of the effect of steroids and probiotics in preventing inflammation in premature infants could be used to design effective therapeutic strategies to prevent the onset of NEC. This is important since NEC is an important public health issue facing premature infants and accounts for 10% of all deaths in the US. PUBLIC HEALTH RELEVANCE: Despite the recent advances of neonatal intensive care, necrotizing enterocolitis (NEC) remains a major health complication for the premature infants and an important cause of neonatal morbidity and mortality. The major risk factors for NEC are prematurity and bacterial colonization. The proposal is designed to determine the mechanism of inflammation in the premature infants that leads to necrotizing enterocolitis. The proposed TLR-mediated signaling in the immature intestine and the steroids and probiotic therapy may accelerate the maturation of innate immune response preventing the onset of necrotizing enterocolitis. The identification of the mechanism and factors involved in this suppression of inflammation could be of tremendous benefit in understanding and preventing NEC in infants.
描述(由申请人提供):Toll样受体(TLR)家族在遇到微生物模式分子、脂多糖[LPS]或肽聚糖[PG]时刺激先天免疫系统。当出生时胃肠道最初被微生物定植时,粘膜先天免疫系统需要减弱,以通过激活TLR途径避免慢性炎症。在足月婴儿中,围产期肠道TLR下调可能提供这种衰减。在这种发育调节之前出生的早产儿中,肠道定植可以激活TLR途径,导致慢性炎症。对细菌暴露的不适当的免疫应答可能导致全身性炎症和肠坏死,例如发生在坏死性小肠结肠炎(NEC)中。在这个提议中,我们将研究TLR受体表达,信号传导和抑制的个体发生,并确定其在调节先天免疫反应中的作用。类固醇和益生菌治疗已被证明可以预防一些易患NEC的早产儿的发病。类固醇作用的机制和益生菌治疗的作用将被确定。将确定防止足月婴儿肠道上皮被微生物群过度激活的益生菌因子。假设是在TLR信号传导途径成熟之前早产儿肠道的定殖可导致NEC特征的婴儿肠道过度炎症。将研究促进健康的益生菌加速TLR途径的负调节物的个体发育,从而防止过度炎症的能力。我们已经开发了用于肠道炎症的特定人体内和体外肠道模型来解决这一假设。我们的具体目标是:(1)TLR受体及其信号中间体和负调节因子的协调下调是否可以防止出生时对细菌定植的过度炎症反应;(2)糖皮质激素预处理通过诱导早产肠道中TLR信号通路的成熟来防止对新定植细菌的高反应性;和(3)益生菌因子通过加速早熟肠道中TLR信号通路的成熟来预防NEC的发作。该项目的成功完成将为TLR信号通路的控制元件的个体发育以及类固醇和益生菌对其的调节提供新的基本信息。这种对类固醇和益生菌在预防早产儿炎症中的作用的机制理解可用于设计有效的治疗策略以预防NEC的发作。这一点很重要,因为NEC是早产儿面临的重要公共卫生问题,占美国所有死亡人数的10%。公共卫生关系:尽管新生儿重症监护取得了进展,但坏死性小肠结肠炎(NEC)仍然是早产儿的主要健康并发症,也是新生儿发病率和死亡率的重要原因。NEC的主要危险因素是早产和细菌定植。该提案旨在确定导致坏死性小肠结肠炎的早产儿炎症机制。提出的TLR介导的信号传导在未成熟的肠道和类固醇和益生菌治疗可能会加速先天免疫反应的成熟,防止坏死性小肠结肠炎的发作。确定这种抑制炎症的机制和因素可能对理解和预防婴儿NEC有巨大的好处。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

W ALLAN WALKER其他文献

W ALLAN WALKER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('W ALLAN WALKER', 18)}}的其他基金

FASEB SRC on Probiotics, Intestinal Microbiota and the Host: Physiological and Cl
FASEB SRC 关于益生菌、肠道微生物群和宿主:生理和氯
  • 批准号:
    8200047
  • 财政年份:
    2011
  • 资助金额:
    $ 46.31万
  • 项目类别:
Barrier Function of the GI Tract in Health and Disease
胃肠道的屏障功能在健康和疾病中的作用
  • 批准号:
    8013264
  • 财政年份:
    2010
  • 资助金额:
    $ 46.31万
  • 项目类别:
Harvard Clinical Nutrition Research Center
哈佛临床营养研究中心
  • 批准号:
    8011157
  • 财政年份:
    2010
  • 资助金额:
    $ 46.31万
  • 项目类别:
Maturation of intestinal innate immunity and NEC
肠道先天免疫和NEC的成熟
  • 批准号:
    8440837
  • 财政年份:
    2009
  • 资助金额:
    $ 46.31万
  • 项目类别:
Barrier Function of the GI Tract in Health and Disease
胃肠道的屏障功能在健康和疾病中的作用
  • 批准号:
    7868666
  • 财政年份:
    2009
  • 资助金额:
    $ 46.31万
  • 项目类别:
BACTERIAL EPITHELIAL CROSSTALK IN DEVELOPING INTESTINE
肠道发育中的细菌上皮细胞串扰
  • 批准号:
    7487450
  • 财政年份:
    2007
  • 资助金额:
    $ 46.31万
  • 项目类别:
Pilot and Feasibility
试点与可行性
  • 批准号:
    7504414
  • 财政年份:
    2007
  • 资助金额:
    $ 46.31万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    7499795
  • 财政年份:
    2007
  • 资助金额:
    $ 46.31万
  • 项目类别:
TISSUE CULTURE MORPHOLOGY TRANSPLANT MODEL
组织培养形态移植模型
  • 批准号:
    7487455
  • 财政年份:
    2007
  • 资助金额:
    $ 46.31万
  • 项目类别:
Barrier Function of the Gi Tract in Health and Disease
胃肠道在健康和疾病中的屏障功能
  • 批准号:
    7499906
  • 财政年份:
    2007
  • 资助金额:
    $ 46.31万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 46.31万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 46.31万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 46.31万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 46.31万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 46.31万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 46.31万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 46.31万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 46.31万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 46.31万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 46.31万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了